Opiod Analgesics and the Risk of Serious Infections in Seniors
Opiod Analgesics and the Risk of Serious Infections in Seniors
批准号:
8370150
负责人:
CARLOS G GRIJALVA
金额:
$7.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-01 至 2014-07-31
关键词:
AddressAffectAnalgesicsCase SeriesClinicalClinical TrialsDataEffectivenessElderlyEnrollmentEpidemiologic StudiesGuidelinesImmune responseImmune systemImmunosuppressionImmunosuppressive AgentsIndividualInfectionKnowledgeLifeMeasuresMedicaidMedicalNon-Steroidal Anti-Inflammatory AgentsObservational StudyOpioidOpioid AnalgesicsOutcomePTGS2 genePainPatientsPersistent painPersonsPharmaceutical PreparationsPharmacotherapyPopulationPropertyPublic HealthRandomized Clinical TrialsRelative RisksResearch DesignRetrospective StudiesRiskSafetySelf-control as a personality traitSeriesTennesseeTestingTimeTranslatingUnited StatesVariantbasedesignfollow-upimprovedin vivoinhibitor/antagonistinterestolder patientresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Opioid analgesics are one of the most commonly prescribed medication classes in the United States. Although these medications have been available for medical use for decades, their safety and effectiveness remain unclear. Available data from clinical trials are limited to highly selected patients and short term efficacy outcomes.
Of great concern, information on the safety profile of these medications is even more scant. Several lines of in vivo experimental evidence indicate that opioid analgesics have significant immunosuppressive properties and could render opioid users susceptible to serious, potentially life-threatening infections. The immunosuppressive effects of opioid analgesics could be particularly troublesome for the elderly, who are commonly affected by persistent pain and are already at increased risk for infections. Given concerns about the safety of alternate analgesics (e.g. NSAIDs and COX-2 inhibitors), and the increasing widespread use of opioids, the determination and quantification of this potential risk is of great public health interest. Furthermore, there are a number of opioid analgesics currently available, but not all are expected to have the same immunosuppressive properties. Identifying those opioids with the lowest propensity to facilitate serious infections will be crucial to inform the selection of analgesics for the elderly. We propose to conduct a retrospective study of elderly persons enrolled in TennCare (Tennessee Medicaid) with the following specific aims: 1) To test the hypothesis that use of opioid analgesics increases the risk of serious infections; and, 2) To test the hypothesis that there is variation of the risk of serious infections for individual opioids. Th proposed studies will use a self-controlled case-series design, in which cases serve as their own controls, cancelling out the effects of fixed measured and unmeasured confounders, allowing control of relevant time-varying covariates; and, thus, allowing an unbiased estimation of the relative risk.
PUBLIC HEALTH RELEVANCE: There is a long-standing concern that opioids can modify the immune system response and increase the risk of infections. These concerns are particularly relevant for elderly persons, who are commonly affected by pain and at increased risk for infections. Given the widespread use of opioid analgesics, the determination and quantification of this potential risk is of great public health interest. Moreover, identifying those opioids withthe lowest propensity to facilitate infections will be crucial to inform the selection of analgesics fo elderly patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Peru Vanderbilt – PREvention through VacciNation Training (PREVENT) program
-
批准号:10674393
-
项目类别:
-
资助金额:$25.14万
-
财政年份:2023
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Human rhinovirus infection and susceptibility to SARS-CoV-2 infection and symptomatic disease
-
批准号:10726391
-
项目类别:
-
资助金额:$27.01万
-
财政年份:2023
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Impact of Pandemic Mitigation Efforts on Colonization and Transmission of Respiratory Pathogens and Antibiotic Resistance Genes
-
批准号:10641008
-
项目类别:
-
资助金额:$21.63万
-
财政年份:2022
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Impact of Pandemic Mitigation Efforts on Colonization and Transmission of Respiratory Pathogens and Antibiotic Resistance Genes
-
批准号:10510137
-
项目类别:
-
资助金额:$25.95万
-
财政年份:2022
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Gestational diabetes drugs and perinatal outcomes in underserved populations
-
批准号:10487395
-
项目类别:
-
资助金额:$25.95万
-
财政年份:2021
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Gestational diabetes drugs and perinatal outcomes in underserved populations
-
批准号:10193041
-
项目类别:
-
资助金额:$21.63万
-
财政年份:2021
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Mentoring in transmission of influenza and strategies for prevention
-
批准号:10555283
-
项目类别:
-
资助金额:$17.86万
-
财政年份:2020
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Mentoring in transmission of influenza and strategies for prevention
-
批准号:10356800
-
项目类别:
-
资助金额:$17.86万
-
财政年份:2020
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Mentoring in transmission of influenza and strategies for prevention
-
批准号:10094190
-
项目类别:
-
资助金额:$17.86万
-
财政年份:2020
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Learning Health System training program: PROgRESS--Patient/ pRactice Outcomes and Research in Effectiveness and Systems Science
-
批准号:10425309
-
项目类别:
-
资助金额:$53.17万
-
财政年份:2018
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Learning Health System training program: PROgRESS--Patient/ pRactice Outcomes and Research in Effectiveness and Systems Science
-
批准号:10192698
-
项目类别:
-
资助金额:$43.78万
-
财政年份:2018
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Learning Health System training program: PROgRESS-- Patient/ pRactice Outcomes and Research in Effectiveness and Systems Science
-
批准号:10747558
-
项目类别:
-
资助金额:$54.0万
-
财政年份:2018
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Household Transmission of Influenza Viruses in the Community
-
批准号:9443433
-
项目类别:
-
资助金额:$49.97万
-
财政年份:2017
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Household Transmission of Influenza Viruses in the Community
-
批准号:10221448
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2017
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Household Transmission of Influenza Viruses in the Community-COVID 19 Supplement
-
批准号:10179276
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2017
-
负责人:CARLOS G GRIJALVA
-
依托单位:
The Impact of Infant Vaccination with a 13-valent Pneumococcal Conjugate Vaccine
-
批准号:9335085
-
项目类别:
-
资助金额:$1.43万
-
财政年份:2014
-
负责人:CARLOS G GRIJALVA
-
依托单位:
The Impact of Infant Vaccination with a 13-valent Pneumococcal Conjugate Vaccine
-
批准号:8702459
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2014
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Opioid selection and the risk of serious infections in older adults
-
批准号:8575766
-
项目类别:
-
资助金额:$56.82万
-
财政年份:2013
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Opioid selection and the risk of serious infections in older adults
-
批准号:8704848
-
项目类别:
-
资助金额:$55.59万
-
财政年份:2013
-
负责人:CARLOS G GRIJALVA
-
依托单位:
Opiod Analgesics and the Risk of Serious Infections in Seniors
-
批准号:8518215
-
项目类别:
-
资助金额:$7.37万
-
财政年份:2012
-
负责人:CARLOS G GRIJALVA
-
依托单位:
海外基金